Replies to post #12686 on Momenta Pharmaceuticals, Inc. (MNTA)

[DewDiligence]

If the only asset MNTA had was Necuparanib entering phase-2, the stock’s EV would probably be $150-200M, IMO. In other words, there’s a valuation disconnect here that’s been caused by the stain from falling short of prior expectations.